132 related articles for article (PubMed ID: 16713012)
41. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
42. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
43. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Rosell R; Ichinose Y; Taron M; Sarries C; Queralt C; Mendez P; Sanchez JM; Nishiyama K; Moran T; Cirauqui B; Mate JL; Besse B; Reguart N; Perez M; Sanchez JJ
Lung Cancer; 2005 Oct; 50(1):25-33. PubMed ID: 16011858
[TBL] [Abstract][Full Text] [Related]
44. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
45. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
46. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
47. Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.
Liu CM; Chiu KL; Chen TS; Chang SM; Yang SY; Chen LH; Ni YL; Sher YP; Yu SL; Ma WL
Biomed Res Int; 2015; 2015():642041. PubMed ID: 25692143
[TBL] [Abstract][Full Text] [Related]
48. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
49. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
50. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
52. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Iwasa T; Yoshida T; Hatashita E; Yamada Y; Satoh T; Tamura K; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2008 Mar; 7(3):599-606. PubMed ID: 18347146
[TBL] [Abstract][Full Text] [Related]
53. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
54. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
55. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
56. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
57. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
[TBL] [Abstract][Full Text] [Related]
58. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.
Hosaka T; Inoue F; Ando K; Ishida H; Kusumoto S; Sugiyama T; Shirai T; Okuda K; Hirose T; Ohnishi T; Horichi N; Saijo N; Adachi M; Nakadate T; Kuroki T; Ohmori T
Anticancer Res; 2007; 27(4B):2253-63. PubMed ID: 17695511
[TBL] [Abstract][Full Text] [Related]
59. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
[TBL] [Abstract][Full Text] [Related]
60. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
